Genoa Ventures

Alida Biosciences is a biotechnology company established in 2020 and based in San Diego, California. The company specializes in developing innovative RNA analysis tools aimed at enhancing human health. By focusing on advancements in RNA biology, Alida Biosciences creates technologies that facilitate the discovery of new drugs and therapeutics. Its work is designed to support the development of medical treatments and diagnostic assays, ultimately enabling patients to access effective healthcare solutions.

Aqtual is a biotechnology diagnostics platform focused on providing innovative healthcare solutions for chronic diseases. The company has developed a novel analytical platform that captures molecular signals from circulating deoxyribonucleic acid, enhancing the sensitivity and specificity of diagnostics. This technology aims to improve the timing and accuracy of disease management, enabling personalized treatment options for cancer patients. By integrating biochemistry with advanced diagnostics, Aqtual strives to transform the approach to cancer care and improve patient outcomes.

BRAINBox Solutions, Inc. is a medical technology company specializing in the development and manufacture of tests for diagnosing and predicting outcomes in mild traumatic brain injury (TBI). Founded in 2002 and headquartered in Richmond, Virginia, BRAINBox Solutions employs a multi-modality approach that integrates blood biomarker panels, neurocognitive testing, and point-of-care instruments. This innovative platform provides healthcare professionals with objective evidence of injury and aids in forecasting patient recovery. By combining injury-related blood protein biomarkers with computerized neurological assessments, BRAINBox Solutions enhances the diagnostic capabilities within the healthcare sector, ultimately aiming to improve patient care and recovery outcomes.

BrightSpec is a company based in Charlottesville, Virginia, specializing in advanced analytical chemistry solutions through its innovative Fourier transform molecular rotational resonance (FT-MRR) spectroscopy platform. This technology, developed by researchers at the University of Virginia, enables comprehensive characterization of chemical molecules, with the capability to differentiate between stereoisomers and isotopes. BrightSpec's platform addresses high-value, time-sensitive analytical challenges that conventional spectroscopy techniques struggle to meet. By eliminating the need for reference samples or separations, its solutions enhance the analysis of complex mixtures, making them particularly valuable for applications in manufacturing process control, quality assurance, environmental monitoring, and formulation research. The company aims to improve the efficiency and accuracy of chemical analysis, thereby transforming the landscape of sample analytics in various industries.

ZwitterCo specializes in advanced membrane solutions for the treatment of highly impaired wastewater, enabling the reuse and recycling of water resources in industrial applications. The company's innovative reverse osmosis and nanofiltration technologies address the challenges of treating historically unfilterable streams by preventing fouling caused by organic molecules. ZwitterCo's membranes are chlorine-tolerant, back-washable, and resistant to irreversible fouling, which enhances their longevity and performance. By transforming wastewater from a liability into a valuable resource, ZwitterCo helps clients manage their water treatment needs more economically and sustainably, reducing chemical demands and improving operational efficiency.

Bond Pet Foods, established in 2015 and based in Boulder, Colorado, specializes in manufacturing pet food products using real animal protein produced through fermentation. The company cultivates animal proteins in a lab setting using biotechnology, eliminating the need for animal slaughter. These proteins are then harvested and formulated into pet nutrition and food products, meeting the specific dietary requirements of companion animals. Bond Pet Foods aims to provide sustainable, all-natural, and animal-free alternatives for pet owners seeking eco-friendly options.

Codetta Bio is a life sciences company focused on developing a novel multi-omic analysis platform that utilizes digital spatial polymerase chain reaction (dsPCR) and digital spatial immuno polymerase chain reaction (dsIPCR). This integrated platform combines reagents, hardware, and software to facilitate multiplexed, multi-omic analyses of liquid biopsies, as well as isolated DNA, RNA, and protein samples. By providing a quantitative and spatially resolved solution, Codetta Bio aims to enhance the understanding of genetic, environmental, lifestyle, and clinical factors that influence individual health. The platform is designed to streamline workflows for researchers, enabling efficient analysis of various targets, including viral and bacterial pathogens, genetic mutations, and protein expressions. Ultimately, the company's innovative technology seeks to accelerate the research and development of next-generation therapies, thereby improving patient care and overall quality of life.

Epitel is a digital health company focused on developing a wearable, wireless EEG monitoring platform aimed at enhancing seizure detection. The company's innovative device utilizes a proprietary cloud-based sensor system combined with advanced artificial intelligence technologies to accurately identify abnormal brain activities. By prioritizing accessibility, affordability, and reliability, Epitel enables physicians, caregivers, and patients with neurological disorders to obtain critical brain health insights, ultimately improving their quality of life and care.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at harnessing the untapped genetic diversity of various organisms. By modulating homologous recombination frequencies in eukaryotic cells, Meiogenix enhances natural biodiversity and facilitates the creation of new products. This approach is designed to help businesses tackle pressing global food and industrial challenges, ultimately contributing to sustainable solutions in these sectors.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which merges advanced simulation techniques with a wide array of experimental datasets. This technology enables researchers to gain insights into the cancer microenvironment, allowing them to observe tumor behavior, including cell phenotypes and interactions with surrounding tissues. By creating personalized virtual tumors from comprehensive diagnostic data, SimBioSys facilitates computational scenario analysis that enhances doctors' understanding of individual cases. This approach aims to improve decision-making and patient experiences in the realm of oncology, ultimately transforming cancer treatment.

InterVenn is a life science company focused on revolutionizing healthcare through the study of glycoproteomics, which involves glycosylated proteins that significantly influence protein function. By developing an innovative AI-powered platform, InterVenn decodes the complex glycoproteome, providing critical biological insights that were previously unattainable. This technology enables the identification, quantification, and classification of glycoproteomic signals in human blood and tissue, facilitating early detection and triaging of cancers, particularly ovarian cancer. InterVenn’s platform supports the creation of a diverse range of clinical applications, from disease screening to diagnostics, and has the potential to contribute to therapeutics. Founded by renowned experts, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn aims to advance personalized, predictive, and preventative healthcare solutions, enhancing patient outcomes and aiding pharmaceutical partners in their research and development efforts.

Stemson Therapeutics, LLC is a cell therapy company focused on restoring natural hair through innovative techniques. Established in 2018 and based in La Jolla, California, the company specializes in generating new hair follicles using a proprietary method that involves induced pluripotent stem cells (iPSC) to create dermal papilla cells. These engineered cells, combined with a unique tissue engineering solution, allow for the generation of new hair follicles, providing a potential cure for individuals experiencing hair loss and its associated emotional and social challenges. Stemson Therapeutics aims to offer patients a safe and effective means to combat hair loss by delivering a new supply of hair follicles.

BloodQ develops an analytical platform designed for cancer drug treatment. Its platform captures disease molecular signals in circulating DNA to improve sensitivity, specificity, and timing in diagnostic and disease management, thereby providing patients personalized cancer treatment.

Attune Neurosciences is a medical device company focused on enhancing human health and performance through the development of clinically proven, non-invasive neurostimulation products. The company aims to address sleep- and wake-related conditions by modulating brain activity, thereby assisting patients suffering from central nervous system disorders. In addition to supporting individual health, Attune Neurosciences also seeks to serve government and industrial applications, positioning its innovative solutions to benefit a broader range of stakeholders.

BRAINBox Solutions, Inc. is a medical technology company specializing in the development and manufacture of tests for diagnosing and predicting outcomes in mild traumatic brain injury (TBI). Founded in 2002 and headquartered in Richmond, Virginia, BRAINBox Solutions employs a multi-modality approach that integrates blood biomarker panels, neurocognitive testing, and point-of-care instruments. This innovative platform provides healthcare professionals with objective evidence of injury and aids in forecasting patient recovery. By combining injury-related blood protein biomarkers with computerized neurological assessments, BRAINBox Solutions enhances the diagnostic capabilities within the healthcare sector, ultimately aiming to improve patient care and recovery outcomes.

InterVenn is a life science company focused on revolutionizing healthcare through the study of glycoproteomics, which involves glycosylated proteins that significantly influence protein function. By developing an innovative AI-powered platform, InterVenn decodes the complex glycoproteome, providing critical biological insights that were previously unattainable. This technology enables the identification, quantification, and classification of glycoproteomic signals in human blood and tissue, facilitating early detection and triaging of cancers, particularly ovarian cancer. InterVenn’s platform supports the creation of a diverse range of clinical applications, from disease screening to diagnostics, and has the potential to contribute to therapeutics. Founded by renowned experts, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn aims to advance personalized, predictive, and preventative healthcare solutions, enhancing patient outcomes and aiding pharmaceutical partners in their research and development efforts.

IonPath Inc., established in 2014 and headquartered in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. The company's core technology surpasses light microscopy, enabling it to analyze fresh, frozen, or FFPE tissues with high precision. This allows healthcare providers to diagnose cancer more accurately, ultimately improving human health through better insights into the tissue microenvironment at a single-cell level.

Tropic Biosciences UK Ltd, established in 2016 and based in Norwich, is a biotechnology company specializing in the development of commercial tropical crops. It employs advanced plant breeding and non-GMO gene editing techniques to create high-performing varieties, catering primarily to the coffee and banana industries. The company's mission is to promote grower wellbeing, consumer health, and sustainable environmental practices through its innovative, non-GMO methods, which significantly accelerate the breeding process to meet growing food demands and local community needs.

Intabio, Inc. is a biotechnology company founded in 2015 and based in Newark, California. It specializes in developing analytical solutions aimed at enhancing the efficiency of biopharmaceutical development and manufacturing. The company’s primary offering is the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of biotherapeutic proteins. Additionally, Intabio's microfluidic platform facilitates real-time characterization of intact protein isoforms, allowing for the identification of specific structural modifications. This technology enables biotherapeutic drug manufacturers to perform comprehensive analyses of antibody and protein biopharmaceuticals, resulting in significant improvements in throughput and cost-effectiveness compared to traditional methods.

InterVenn is a life science company focused on revolutionizing healthcare through the study of glycoproteomics, which involves glycosylated proteins that significantly influence protein function. By developing an innovative AI-powered platform, InterVenn decodes the complex glycoproteome, providing critical biological insights that were previously unattainable. This technology enables the identification, quantification, and classification of glycoproteomic signals in human blood and tissue, facilitating early detection and triaging of cancers, particularly ovarian cancer. InterVenn’s platform supports the creation of a diverse range of clinical applications, from disease screening to diagnostics, and has the potential to contribute to therapeutics. Founded by renowned experts, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn aims to advance personalized, predictive, and preventative healthcare solutions, enhancing patient outcomes and aiding pharmaceutical partners in their research and development efforts.

Intabio, Inc. is a biotechnology company founded in 2015 and based in Newark, California. It specializes in developing analytical solutions aimed at enhancing the efficiency of biopharmaceutical development and manufacturing. The company’s primary offering is the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of biotherapeutic proteins. Additionally, Intabio's microfluidic platform facilitates real-time characterization of intact protein isoforms, allowing for the identification of specific structural modifications. This technology enables biotherapeutic drug manufacturers to perform comprehensive analyses of antibody and protein biopharmaceuticals, resulting in significant improvements in throughput and cost-effectiveness compared to traditional methods.

IonPath Inc., established in 2014 and headquartered in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. The company's core technology surpasses light microscopy, enabling it to analyze fresh, frozen, or FFPE tissues with high precision. This allows healthcare providers to diagnose cancer more accurately, ultimately improving human health through better insights into the tissue microenvironment at a single-cell level.

NanoCellect Biomedical, Inc., established in 2009 and headquartered in San Diego, California, specializes in developing innovative flow cytometry and cell sorting solutions for life science researchers. The company's flagship product, the WOLF Cell Sorter, employs a unique closed fluid-path microfluidic cartridge to facilitate efficient cell sorting while mitigating biohazard risks and shear stress issues common in traditional methods. Their portfolio of affordable, compact, and user-friendly instruments and consumables caters to various applications such as drug discovery, single-cell omics, cloning, antibody discovery, and basic research, empowering biomedical scientists with simplified cellular analysis and sorting capabilities.

Intabio, Inc. is a biotechnology company founded in 2015 and based in Newark, California. It specializes in developing analytical solutions aimed at enhancing the efficiency of biopharmaceutical development and manufacturing. The company’s primary offering is the Blaze system, which includes a bench-top instrument, microfluidic chip, and reagent kit designed for the separation, quantitation, and molecular mass identity analysis of biotherapeutic proteins. Additionally, Intabio's microfluidic platform facilitates real-time characterization of intact protein isoforms, allowing for the identification of specific structural modifications. This technology enables biotherapeutic drug manufacturers to perform comprehensive analyses of antibody and protein biopharmaceuticals, resulting in significant improvements in throughput and cost-effectiveness compared to traditional methods.

Akadeum Life Sciences, Inc. is a life sciences company based in Ann Arbor, Michigan, specializing in the manufacturing of microbubble cell separation products. Founded in 2014, the company develops bioseparation products that utilize microscopic microbubbles to efficiently capture and isolate target cells from biological samples. Their offerings include T cell and B cell isolation kits for both human and mouse cells, as well as depletion microbubbles for red blood cell separation. Akadeum's products streamline the process of removing specific cells, such as bacteria or viruses, from liquid samples, thereby enhancing the efficiency of downstream testing and analysis. The company also collaborates with strategic partners, including Agilent Technologies, to further advance its innovative solutions in cell separation. Akadeum Life Sciences sells its products online, aiming to improve cell-based research and diagnostics in the life sciences sector.

Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, that specializes in developing a rapid and label-free biological assay platform for clinical and point-of-care samples. Founded in 2008, the company utilizes its innovative arrayed imaging reflectometry technology to enable the simultaneous detection of hundreds of analytes from a single drop of fluid. This platform allows healthcare professionals to conduct sophisticated tests in a matter of minutes, ensuring high sensitivity and specificity in the detection of multiplexed proteins. Adarza BioSystems aims to enhance diagnostic capabilities, improving patient outcomes through quicker and more accurate testing.

Synthomics, Inc. specializes in oligonucleotide synthesis solutions, providing advanced RNA and DNA synthesizers that enhance the efficiency and quality of oligonucleotide production. Based in Menlo Park, California, the company develops products for diverse applications, including research, diagnostics, pharmaceuticals, and agriculture. Their innovative synthesizer can accommodate up to 1,536 unique oligonucleotides simultaneously, significantly surpassing the industry standard of 96. This capability not only reduces reagent consumption but also lowers costs and improves turnaround times. Synthomics' flagship "Green Machine" further streamlines DNA synthesis, achieving cost reductions of 20 to 100 times while minimizing waste and enhancing overall quality. Their solutions support critical processes such as next generation sequencing, gene synthesis, gene editing, and PCR, making significant contributions to life sciences innovation.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

Pivot Bio, Inc. is a biotechnology company founded in 2010 and based in Emeryville, California. The company focuses on enhancing crop nutrition through a deep understanding of the microbiome, utilizing engineered microbes to deliver essential nutrients, protect against pests, and improve crop quality. By leveraging data science and engineering principles, Pivot Bio aims to map the dynamics of the plant microbiome and develop beneficial traits. Their proprietary ON Technology utilizes naturally occurring microbes to supply nitrogen to crops, offering a sustainable alternative to synthetic fertilizers. This innovation not only helps farmers increase yields but also contributes to reducing reliance on petrochemical fertilizers, ultimately promoting healthier ecosystems and cleaner air and water. Pivot Bio's current initiatives primarily focus on enabling microbes to fix and supply nitrogen for corn, addressing the growing need for sustainable agricultural practices as the global population expands.

IonPath Inc., established in 2014 and headquartered in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. The company's core technology surpasses light microscopy, enabling it to analyze fresh, frozen, or FFPE tissues with high precision. This allows healthcare providers to diagnose cancer more accurately, ultimately improving human health through better insights into the tissue microenvironment at a single-cell level.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in developing and commercializing innovative tools for protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. By utilizing microfluidics technology, the scWestern system partitions single cells into micro-wells, lyses them, and performs SDS-PAGE separation on each cell lysate. This technology facilitates the identification of cellular subpopulations, the analysis of enriched cell populations post-FACS sorting, and studies on cell signaling and cancer heterogeneity, among other applications. Researchers leverage Zephyrus's products to gain deeper insights into various biological fields, including cancer, stem cells, neurology, and human disease development, ultimately aiming to enhance healthcare outcomes.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.